The purpose of this study is to evaluate a new treatment routine for patients with metastatic HER2 -positive breast cancer. We want to find out what effects, good and bad, using a Poly (ADP-Ribose) polymerase (PARP) inhibitor called niraparib in combination with trastuzumab has on patients with metastatic HER2- positive breast cancer.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

Have you been diagnosed with locally advanced or metastatic hepatocellular carcinoma? If so, you may be a good fit to help us learn if adding tiragolumab to standard therapy could help you and others with your condition

If you have high risk prostate cancer, you may be able to participate in a research study to find out decreasing or increasing your radiation and hormonal therapy has an effect on your cancer.

In this study, we want to learn if a combination of two drugs (fianlimab and cemiplimab) is an effective treatment compared to a drug called pembrolizumab for people who have had melanoma removal surgery but are still at high risk for recurrence of the disease.

This is a Phase 1b/2, multicenter, open-label, basket study evaluating ACR-368, an adenosine triphosphate-competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2, as monotherapy and in combination with ultralow-dose gemcitabine (ULDG), in the treatment of subjects with histologically confirmed, locally advanced or metastatic, recurrent platinum-resistant high-grade ovarian or endometrial adenocarcinoma, or platinum-resistant urothelial carcinoma (hereafter referred to as ovarian, endometrial, and urothelial, respectively).

Have you been diagnosed with a locally advanced or metastatic solid tumor cancer? Are there no available curative treatment options, or has your prior standard of care treatment failed? You may be able to take part in this gene therapy research study to learn more about using your own modified immune cells as a possible treatment.

If you have Testosterone-driven Salivary Gland Cancer, you may be able to participate in a research study testing the anti-cancer drug Darolutamide.